← Back to Search

Other

Red-light Therapy for Near-sightedness

N/A
Recruiting
Led By Julius Oatts, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial showed that 3 minutes of low-level red-light technology twice a day can control 87.7% of myopia progression and 76.8% of axial length elongation. This could be a potential global solution for myopia control.

Who is the study for?
This trial is for kids aged 8-13 with near-sightedness (myopia) between -1.00 and -5.00 diopters, less than 1.50 diopters of anisometropia, and up to 2.50 diopters of astigmatism who speak English and have good corrected vision. It's not for those with eye abnormalities, previous myopia treatments, or severe disabilities.
What is being tested?
The study tests a low-level red-light therapy device as a treatment for myopia in children from diverse backgrounds by having them undergo short light sessions twice daily to see if it can control the progression of their near-sightedness effectively.
What are the potential side effects?
While specific side effects are not listed here, similar light therapies have been associated with minimal risks such as mild discomfort or temporary visual disturbances.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Axial Length (AL) (mm) at Baseline
Axial Length (AL) (mm) at Month 1
Axial Length (AL) (mm) at Month 3
+2 more
Secondary study objectives
Anterior Chamber Depth (ACD) at Baseline
Anterior Chamber Depth (ACD) at Month 1
Anterior Chamber Depth (ACD) at Month 3
+32 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Low Level Red Light Treatment ArmExperimental Treatment1 Intervention
On top of wearing single vision spectacles, subjects in the intervention group will receive low-level red light treatment twice a day from Monday to Friday, with each treatment lasting for 3 minutes at a minimal interval of 4 hours.
Group II: Control Treatment ArmActive Control1 Intervention
Subjects in the control group will wear single vision spectacles.

Find a Location

Who is running the clinical trial?

University of MelbourneOTHER
181 Previous Clinical Trials
1,282,153 Total Patients Enrolled
University of California, San FranciscoLead Sponsor
2,587 Previous Clinical Trials
14,901,086 Total Patients Enrolled
Julius Oatts, MDPrincipal InvestigatorUniversity of California, San Francisco
3 Previous Clinical Trials
190 Total Patients Enrolled

Media Library

Low-level Red Light Therapy Device (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05606237 — N/A
Near-sightedness Research Study Groups: Low Level Red Light Treatment Arm, Control Treatment Arm
Near-sightedness Clinical Trial 2023: Low-level Red Light Therapy Device Highlights & Side Effects. Trial Name: NCT05606237 — N/A
Low-level Red Light Therapy Device (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05606237 — N/A
~26 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top